Acute myeloid leukemia (AML) is the
leading cause of leukemia mortality in the United States.1 Curative treatment involves intensive induction chemotherapy, before proceeding to either consolidation chemotherapy or allogeneic stem cell transplantation based on the patient's risk for relapse.2 This approach has been employed for > 4 decades and, although most individuals achieve complete remissions with front - line therapy, 3 the majority of patients ultimately relapse with drug - resistant disease, and overall survival rates
remain disappointingly poor.4 The limited ability of many patients to tolerate the intense chemotherapy - based treatments, in particular hematological
toxicity, further contributes to the poor outcomes noted in this disease.